298 patents
Page 6 of 15
Utility
Tricyclic Heterocyclic Compounds As Sting Activators
10 Mar 22
The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
Filed: 2 Mar 21
Utility
Vinyl Imidazole Compounds As Inhibitors of Kras
3 Mar 22
Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
Filed: 27 Aug 21
Utility
Tricyclic Urea Compounds As JAK2 V617F Inhibitors
3 Mar 22
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 26 Aug 21
Utility
Process and Intermediates for Preparing a JAK1 Inhibitor
24 Feb 22
The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
Filed: 17 Aug 21
Utility
Process and Intermediates for Preparing a Jak Inhibitor
24 Feb 22
The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia
Filed: 17 Aug 21
Utility
Heteroaryl Amide Compounds As Sting Activators
24 Feb 22
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
Filed: 6 Jan 20
Utility
Processes for the Preparation of Arginase Inhibitors and Their Synthetic Intermediates
10 Feb 22
Joseph SCLAFANI, Anthony J. Tomaine, Robert J. Wilson, Daniel Carper, Wayne Han, George Shi, Feiquiang Sun, Guobiao Lu, Jack Liang
Filed: 16 Jul 21
Utility
JAK1 Pathway Inhibitors for the Treatment of Cytokine-related Disorders
10 Feb 22
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
Filed: 19 Jul 21
Utility
Systems, Methods, and Computer Programs, for Analyzing Images of a Portion of a Person to Detect a Severity of a Medical Condition
10 Feb 22
Methods, systems, and computer programs for monitoring skin condition of a person.
Julian Jenkins, Todd Leathers, Ryad Ali
Filed: 5 Aug 21
Utility
Salts and Processes of Preparing a PI3K Inhibitor
27 Jan 22
The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.
Lei Qiao, Lingkai Weng, Chongsheng Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou
Filed: 1 Jul 21
Utility
Sustained Release Dosage Forms for a JAK1 Inhibitor
20 Jan 22
This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Filed: 28 May 21
Utility
Pyrazolopyrimidine Compounds and Uses Thereof
20 Jan 22
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
Filed: 4 Aug 21
Utility
Bicyclic Heterocycles As FGFR4 Inhibitors
13 Jan 22
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
Filed: 23 Apr 21
Utility
DIHYDROPYRIDO[2,3-D]PYRIMIDINONE Compounds As CDK2 Inhibitors
13 Jan 22
The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
Tricyclic Pyridone Compounds As JAK2 V617F Inhibitors
6 Jan 22
The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
Filed: 1 Jul 21
Utility
ALK2 Inhibitors for the Treatment of Anemia
23 Dec 21
Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.
Francis Séguy, Ekaterine Asatiani, Yaoyu Chen
Filed: 15 Jun 21
Utility
Pyrrolotriazine Compounds As JAK2 V617F Inhibitors
23 Dec 21
The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 17 Jun 21
Utility
Bicyclic Heterocycles As FGFR Inhibitors
23 Dec 21
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
Filed: 28 Jan 21
Utility
Heterocyclic Derivatives As PI3K Inhibitors
23 Dec 21
Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
Filed: 24 Jun 21
Utility
Naphthyridinone Compounds As JAK2 V617F Inhibitors
23 Dec 21
The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
Filed: 17 Jun 21